Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Legal ‘Squishiness,’ DoJ Reorganization Could Shape Ad/Promo Enforcement Strategy
Oct 20 2025
•
By
Sue Sutter
Attorneys say some of the FDA warning and untitled letters raise "squishy" claims about misleading ads.
(Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Marketing & Advertising
More from FDLI